Acucort AB (ACUC)

Overview

AcuCort AB (publ) is a healthcare-focused company established in 2006, with its groundwork in Lund, Sweden. The company is dedicated to the development and commercialization of innovative treatments utilizing glucocorticoid dexamethasone films. These treatments are primarily aimed at addressing acute allergic reactions and other medical conditions requiring quick and effective glucocorticoid therapy. AcuCort's pioneering approach leverages the fast-acting properties of dexamethasone in a film format, ensuring rapid absorption and relief for patients dealing with severe allergic reactions and other conditions necessitating prompt glucocorticoid administration.

Products and Services

AcuCort AB offers a unique product, Zeqmelit, which stands as the cornerstone of its product lineup. This innovative medicine is designed to provide rapid relief in several critical and acute conditions:

• Severe and Acute Allergic Reactions: Zeqmelit is formulated to promptly alleviate the symptoms associated with severe allergic reactions. This quick intervention is crucial in preventing the escalation of symptoms and ensuring patient safety.
• Croup in Children: Recognizing the urgency and distress caused by croup in children, Zeqmelit offers a fast-acting solution to relieve the inflammation and breathing difficulties associated with this condition.
• Chemotherapy-Induced Nausea and Vomiting: For cancer patients undergoing chemotherapy, Zeqmelit provides a means to combat the often debilitating nausea and vomiting caused by treatment, thereby improving the quality of life and allowing patients to better tolerate their cancer therapy.
• Treatment of COVID-19 Patients: In response to the global COVID-19 pandemic, Zeqmelit has been positioned as an adjunctive treatment for patients suffering from the virus who require supplemental oxygen. This application underscores the versatility of Zeqmelit and AcuCort AB’s commitment to addressing emergent health crises.